Whole cancer genome sequencing by next-generation methods

American Journal of Clinical Pathology

Volumn 136, Issue 4, 2011, Pages 527-539

  Ross, Jeffrey S ^a,b   Cronin, Maureen ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

Cancer; Colorectal cancer; Massively parallel sequencing; Melanoma; Molecular diagnostics; Next generation sequencing; Non small cell lung cancer; Personalized oncology

Indexed keywords

CETUXIMAB; CRIZOTINIB; DASATINIB; DNA; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PANITUMUMAB; RETINOIC ACID; SUNITINIB; TRASTUZUMAB;

BREAST CANCER; CANCER GENETICS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DIGESTIVE SYSTEM CANCER; DNA SEQUENCE; EPIGENETICS; EXOME; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE TRANSLOCATION; GENOME ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PYROSEQUENCING; REVIEW; SARCOMA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTITUTION REACTION; THYROID CANCER; TUMOR CELL; TUMOR GENE;

GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 80053508491     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPR1SVT1VHUGXW     Document Type: Review

References (75)

1. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010;36(suppl 3):S21-S29.
2. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol. 2009;7:45-53, 64.
3. Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15:390-404.
4. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24:985-995. (Pubitemid 44215393)
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
6. Smalley KS. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs. 2010;11:699-706.
7. Hallberg B, Palmer RH. Crizotinib: latest champion in the cancer wars [editorial]? N Engl J Med. 2010;363:1760-1762.
8. Robson M, Offit K. Inherited predisposition to cancer: introduction and overview. Hematol Oncol Clin North Am. 2010;24:793-797.
9. Weinstein JL, Ayyanar K, Watral MA. Cancer predisposition syndromes. Cancer Treat Res. 2009;150:223-238.
10. Deeken JF, Figg WD, Bates SE, et al. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs. 2007;18:111-126. (Pubitemid 44967422)
11. Bernig T, Chanock SJ. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn. 2006;6:319-331. (Pubitemid 44174338)
12. Algeciras-Schimnich A, O'Kane DJ, Snozek CL. Pharmacogenomics of tamoxifen and irinotecan therapies. Clin Lab Med. 2008;28:553-567.
13. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009;18:R163-R168.
14. Swanton C, Caldas C. From genomic landscapes to personalized cancer management: is there a roadmap? Ann N Y Acad Sci. 2010;1210:34-44.
15. Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now? J Pathol. 2011;223:318-326.
16. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463-5467.
17. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
18. International Human Genome Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-945.
19. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-792. (Pubitemid 40271173)
20. Sequist LV, Joshi VA, Jänne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007;12:90-98. (Pubitemid 46143506)
21. Cooper WA, O'toole S, Boyer M, et al. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 2011;43:103-115.
22. Monzon FA, Ogino S, Hammond ME, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133:1600-1606.
23. Ross JS, Torres-Mora J, Wagle N, et al. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010;134:478-490.
24. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12:35-42.
25. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715-721.
26. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
27. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465-472.
28. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009;4:e7287. doi:10.1371/journal.pone.0007287.
29. Tejpar S, Popovici V, Delorenzi M, et al. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [abstract]. J Clin Oncol. 2010;28(suppl 15):7s. Abstract A-3505.
30. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
31. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer [published online ahead of print February 2, 2011]. Clin Cancer Res. 2011;17:2081-2086. doi:10.1158/1078-0432.CCR-10-1591.
32. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18:548-551.
33. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11:1477-1490.
34. Martín-Broto J, Rubio L, Alemany R, et al. Clinical implications of KIT and PDGFRA genotyping in GIST. Clin Transl Oncol. 2010;12:670-676.
35. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol. 2011;223:251-261.
36. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80:568-574.
37. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28:5219-5228.
38. Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009;23:397-414.
39. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-365. (Pubitemid 28340773)
40. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin Chim Acta. 2006;363:83-94. (Pubitemid 41748205)
41. Marsh S. Pyrosequencing applications. Methods Mol Biol. 2007;373:15-24.
42. Ronaghi M, Shokralla S, Gharizadeh B. Pyrosequencing for discovery and analysis of DNA sequence variations. Pharmacogenomics. 2007;8:1437-1441. (Pubitemid 350162855)
43. Gut IG. DNA analysis by MALDI-TOF mass spectrometry. Hum Mutat. 2004;23:437-441. (Pubitemid 38569215)
44. Edwards JR, Ruparel H, Ju J. Mass-spectrometry DNA sequencing. Mutat Res. 2005;573:3-12.
45. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem. 2005;38:335-350. (Pubitemid 40342864)
46. Higuchi R, Fockler C, Dollinger G. Kinetic PCR: real-time monitoring of DNA amplification reactions. Biotechnology. 1993;11:1026-1030. (Pubitemid 23254023)
47. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986-994. (Pubitemid 26388091)
48. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem. 2000;46:1929-1938.
49. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem. 1997;245:154-160. (Pubitemid 27082244)
50. Dabritz J, Hanfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer. 2005;92:405-412. (Pubitemid 40343159)
51. Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods. 2008;5:16-18.
52. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009;55:641-658.
53. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685-696.
54. Schweiger MR, Kerick M, Timmermann B, et al. The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev. 2011;30:199-210. doi:10.1007/s10555-011-9278-z.
55. Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet. 2010;11:31-46.
56. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks [published online ahead of print October 26, 2010]. Pharmacogenomics J. 2011;11:81-92. doi:10.1038/tpj.2010.81.
57. Church GM. Genomes for all. Sci Am. 2006;294:46-54.
58. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9:387-402.
59. Erlich Y, Mitra PP, delaBastide M, et al. Alta-Cyclic: a self-optimizing base caller for next-generation sequencing. Nat Methods. 2008;5:679-682.
60. Quail MA, Kozarewa I, Smith F, et al. A large genome center's improvements to the Illumina sequencing system. Nat Methods. 2008;5:1005-1010.
61. Ding L, Wendl MC, Koboldt DC, et al. Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet. 2010;19:R188-R196.
62. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437:376-380. (Pubitemid 41613494)
63. Tawfik DS, Griffiths AD. Man-made cell-like compartments for molecular evolution. Nat Biotechnol. 1998;16:652-656. (Pubitemid 28334323)
64. Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science. 2005;309:1728-1732. (Pubitemid 41285943)
65. Braslavsky I, Hebert B, Kartalov E, et al. Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci U S A. 2003;100:3960-3964. (Pubitemid 36418139)
66. Rusk N. Torrents of sequence. Nat Methods. 2011;8:44. doi:10.1038/nmeth.f.330.
67. Schwartz S, Oren R, Ast G. Detection and removal of biases in the analysis of next-generation sequencing reads. PLoS One. 2011;6:e16685. doi:10.1371/journal.pone.0016685.
68. Cantacessi C, Jex AR, Hall RS, et al. A practical, bioinformatic workflow system for large data sets generated by next-generation sequencing. Nucleic Acids Res. 2010;38:e171. doi:10.1093/nar/gkq667.
69. Koboldt DC, Ding L, Mardis ER, et al. Challenges of sequencing human genomes. Brief Bioinform. 2010;11:484-498.
70. Buehler B, Hogrefe HH, Scott G, et al. Rapid quantification of DNA libraries for next-generation sequencing. Methods. 2010;50:S15-S18.
71. Teer JK, Bonnycastle LL, Chines PS, et al. Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. Genome Res. 2010;20:1420-1431.
72. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
73. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161:1961-1971. (Pubitemid 35434840)
74. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology. Arch Pathol Lab Med. 2008;132:1929-1935.
75. Wang F, Wang L, Briggs C, et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007;9:441-451. (Pubitemid 47434110)